402 related articles for article (PubMed ID: 11418366)
21. [Quantification of PML/RAR alpha fusion gene transcripts in patients with acute promyelocytic leukemia by using real-time quantitative PCR].
Lin J; Han LX; Qian J; Wang YL; Qian Z; Yang XF; Sheng XJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Jun; 25(3):319-21. PubMed ID: 18543226
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
23. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.
Jurcic JG; Nimer SD; Scheinberg DA; DeBlasio T; Warrell RP; Miller WH
Blood; 2001 Nov; 98(9):2651-6. PubMed ID: 11675334
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
26. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.
Perego RA; Marenco P; Bianchi C; Cairoli R; Urbano M; Nosari AM; Muti G; Morra E; Del Monte U
Leukemia; 1996 Feb; 10(2):207-12. PubMed ID: 8637228
[TBL] [Abstract][Full Text] [Related]
27. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party.
Grimwade D; Howe K; Langabeer S; Davies L; Oliver F; Walker H; Swirsky D; Wheatley K; Goldstone A; Burnett A; Solomon E
Br J Haematol; 1996 Sep; 94(3):557-73. PubMed ID: 8790159
[TBL] [Abstract][Full Text] [Related]
28. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
29. Cytogenetic, fluorescent in situ hybridization & reverse transcriptase-polymerase chain reaction analysis in acute promyelocytic leukaemia patients.
Shivakumar S; Poonkhuzhali B; Gunasekaran S; Srivastava A; Chandy M
Indian J Med Res; 2002 Feb; 115():59-67. PubMed ID: 12138666
[TBL] [Abstract][Full Text] [Related]
30. [Comparisons of conventional and normalized calculation of quantitative real-time RT-PCR detecting PML-RAR alpha fusion gene in patients with acute promyelocytic leukemia].
Hu J; Gao XD; Liu YF; Zhu YM; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 May; 29(5):304-7. PubMed ID: 18844066
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
32. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
[TBL] [Abstract][Full Text] [Related]
33. Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse.
Huang W; Sun GL; Li XS; Cao Q; Lu Y; Jiang GS; Zhang FQ; Chai JR; Wang ZY; Waxman S
Blood; 1993 Aug; 82(4):1264-9. PubMed ID: 8394752
[TBL] [Abstract][Full Text] [Related]
34. [Expression of PML-RAR alpha fusion transcripts detection by using RQ-PCR].
Han LX; Lin J; Qian J; Wang YL; Qian Z; Yang XF; Sheng XJ; Yao DM
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):753-6. PubMed ID: 19176013
[TBL] [Abstract][Full Text] [Related]
35. Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols.
Bolufer P; Lo Coco F; Grimwade D; Barragán E; Diverio D; Cassinat B; Chomienne C; Gonzalez M; Colomer D; Gomez MT; Marugan I; Román J; Delgado MD; García-Marco JA; Bornstein R; Vizmanos JL; Martinez B; Jansen J; Villegas A; de Blas JM; Cabello P; Sanz MA
Haematologica; 2001 Jun; 86(6):570-6. PubMed ID: 11418365
[TBL] [Abstract][Full Text] [Related]
36. Assessment of residual disease in acute leukemia by means of polymerase chain reaction.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Pérez-Romano B; Ruiz-Argüelles A; Ramírez-Cisneros FJ; López-Martínez B; López-Tapia JD; Rivadeneyra-Espinoza L
Rev Invest Clin; 2000; 52(2):118-24. PubMed ID: 10846434
[TBL] [Abstract][Full Text] [Related]
37. When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).
Cassinat B; de Botton S; Kelaidi C; Ades L; Zassadowski F; Guillemot I; Schlageter MH; Raffoux E; Harousseau JL; Legrand O; Escoffre-Barbe M; Reman O; Gardembas M; Himberlin C; Cahn JY; Guyotat D; Bouscary D; Parry A; Rousselot P; Baruchel A; Dombret H; Chevret S; Fenaux P; Chomienne C
Leuk Res; 2009 Sep; 33(9):1178-82. PubMed ID: 19167754
[TBL] [Abstract][Full Text] [Related]
38. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Meloni G; Diverio D; Vignetti M; Avvisati G; Capria S; Petti MC; Mandelli F; Lo Coco F
Blood; 1997 Aug; 90(3):1321-5. PubMed ID: 9242568
[TBL] [Abstract][Full Text] [Related]
39. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
40. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
